This website uses cookies
Read our Privacy policy and Terms of use for more information.
Long Form Content
Jul 15, 2024
•
6 min read
AbbVie's Rinvoq label expansion application, semaglutide correlates with lowered dementia risks, IDEAYA Biosciences raises over $300M through public offering, two health SPACS launch with a combined $400M, Spark Therapeutics layoffs, and Big Pharma & PBMs play drug price blame game
Jul 12, 2024
7 min read
Pfizer's one-daily obesity pill moves forward, Illumina competitor lands $277M Series D, Novo Nordisk once-weekly insulin injection rejected by FDA, Novartis to shutter San Diego R&D site, and FTC sues Pharmacy Benefit Managers over insulin prices
Jul 11, 2024
8 min read
Flagship raises a colossal $3.5B 8th round, Illumina buys Fluent Biosciences, Pfizer and Evoteic sign drug discovery pact, Amylyx buys a Ph3 ready GLP-1 asset, and Allucent tapped for BARDA decentralized clinical trial initiative
Jul 10, 2024
FTC comes out swinging against PBMs, uniQure stock jumps on Huntington's data, new anti-inflammatory player raises $70M, J&J sweeps aside two lawsuits, and Interius BioTherapeutics ok'd for first in-human in-vivo CAR-T trial
Jul 9, 2024
Eli Lilly buys Morphic for $3.2B, Roche gets FDA approval for Vabysmo prefilled syringe, SmartCella raises €50M (half from Novartis), and Eli Lilly bests Novo Nordisk in weight-loss head-to-head, Grifols may go private
Jul 8, 2024
5 min read
Another ADC Biotech bags $100M+ in funding, Lotte Biologics' groundbreaking for multibillion $ project, CSL Behring's Hemophilia B gene therapy has its first two patients, and GLP-1s reduce risk of obesity-linked cancers in diabetics
Jul 7, 2024
🧬 Winners, Losers, and Upcoming Earnings Calls
Jul 5, 2024
Beacon Therapeutics raises $170M Series B, Pentixapharm acquires Glycotope's antibody discovery arm, J&J lands FDA and EMA approval for multi-drug resistant TB therapy, and CureVac sells its Covid-19/flu assets while also laying off 30% of their staff
Jul 3, 2024
9 min read
Eli Lilly lands key Alzheimer's FDA approval, Samsung Biologics scores whopper $1B CDMO contract, Annovis Bio has a great day on positive Ph3 Parkinson's data, and Americans don't know which pharma makes weight-loss drugs
Jul 2, 2024
Eli Lilly makes another radiopharma deal, Samsung's Stelara biosimilar gets FDA approval, Boehringer Ingelheim begins Ph1 for "first-in-class" obesity treatment, Takeda sheds over 200 MA-based staffers, and lone Ph1 ultra-rare disease gene therapy patient makes stellar improvements
Jul 1, 2024
Abbvie, Regeneron, Merck & Co. all land CHMP panel recommendations (while Apellis and PTC both get thumbs down), Lantheus buys radiophama assets, Ensho Therapeutics launches with Eisai assets, and former Cassava Sciences scientific advisor gets indicted
Jun 29, 2024
